Boston Scientific announces results for third quarter 2026
Article excerpt
Highlighted: the sentence this signal was extracted from
MARLBOROUGH, Mass., Oct. 28, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) generated net sales of $5.138 billion during the third quarter of 2026, growing 1.5 percent on a reported, operational 1 and organic 2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $582 million or $0.40 per share (EPS), compared to $755 million or $0.51 per share a year ago, and achieved adjusted 3 EPS of $0.73 for the period, compared to $0.75 a year ago. "This has been a challenging year for Boston Scientific and I'm proud of how our global teams have responded, particularly to the cybersecurity incident, working with urgency and resilience to restore operations and continue supporting customers and patients," said Mike Mahoney, chairman and chief executive officer, Boston Scientific. "As we move forward, I remain confident in our long-term strategy, fueled by our dedicated talent, differentiated portfolio and strong pipeline of meaningful innovation." Third quarter financial results and recent developments: 1. Operational net sales growth excludes the impact of foreign currency fluctuations. 2. Organic net sales growth excludes the impact of foreign currency fluctuations and net sales attributable to certain acquisitions and divestitures for which there are less than a full period of...
Keep reading with a free account
The rest of this article, and every signal for Boston Scientific, is in your free account.
